Trial Profile
Prospective, open, multicenter, single arm clinical study of atapatinib combined with docetaxel in the treatment of HER2 negative
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- 16 May 2018 New trial record